...
TGTXMID

TG Therapeutics, Inc.

HealthcareBiotechnology
$30.09
$0.01(-2.62%)
52W$25.28
$46.48
FinancialsValuationvs ARGX
Updated Mar 3, 12:00 AM
RSI58
RS Rating38/99
Beta0.43
Volatility49%
F-Score3/9
Mkt Cap$4.8B
WEAKENING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

WEAKENING

TG Therapeutics, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 38), showing significant lag compared to the market leaders. Earnings growth of 294% provides fundamental context to the price action. A decisive close above the 200-day moving average is required to signal a potential trend reversal.

Relative Strength
38
out of 99
Lagging
Trend Score
1/4
Minervini Criteria
WEAKENING
Risk (Beta)
0.43
vs S&P 500
LOW VOL
52W Position
23%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

WEAKENING1/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$29.91
50 SMA > 100 SMA$31.34
100 SMA > 150 SMA$31.45
150 SMA > 200 SMA$32.74

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$29.36+2.50%ABOVE
50 SMA$29.91+0.60%ABOVE
100 SMA$31.34-3.98%BELOW
150 SMA$31.45-4.32%BELOW
200 SMA$32.74-8.09%BELOW

Price Performance

1D-2.6%
1W-1.6%
1M-0.7%
3M-9.5%
6M+3.9%
YTD+2.8%
1Y+0.0%
3Y+23.4%
52-Week Trading Range23% from low
$30.09
52W Low$25.28
52W High$46.48

Technical Indicators

RSI (14)NEUTRAL
58.1
305070
VCP ScoreCOOL
6/10
Base depth: 21.1%

Risk Profile

Beta
0.43
52W Vol
49%
ATR
$1.19
Max DD (1Y)
-42%

Volume Analysis

Today
30
50D Avg
1.65M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q3'24-97%
$0.02
Q4'24+250%
$0.15
Q1'25+142%
$0.03
Q2'25+294%
$0.17
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+115.49%
5 Years:+364.59%
3 Years:+266.39%
TTM:+30.96%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-38.15%

Stock Price CAGR

10 Years:+13.70%
5 Years:-7.73%
3 Years:+23.38%
1 Year:+0.00%

Return on Equity

10Y Avg:-166.6%
5Y Avg:-63.9%
3Y Avg:-42.5%
Last Year:21.9%

Key Metrics

Market Cap$4.8B
Gross Margin88.3%
Net Margin7.1%
Piotroski F-Score3/9

More TGTX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

TGTX vs ARGXARGXCANFAKTXABVX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 38 meansTGTX outperformed 38% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.43 means 56% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 3/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 6/10 with COOL status.

Frequently Asked Questions

Is TGTX in an uptrend right now?

TGTX has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.

Is TGTX overbought or oversold?

TGTX's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.

Is TGTX outperforming the market?

TGTX has a Relative Strength (RS) Rating of 38 out of 99. TGTX is currently lagging the broader market.

Where is TGTX in its 52-week range?

TGTX is trading at $30.09, which is 65% of its 52-week high ($46.48) and 23% above its 52-week low ($25.28).

How volatile is TGTX?

TGTX has a Beta of 0.43 and 52-week volatility of 49%. It's less volatile than the S&P 500 - generally more stable.